

CRATON MERIDIAN

AI INTEGRITY

---

# The Label Says Otherwise

What Eight AI Platforms Get Wrong  
About GLP-1 Medications

---

Research Publication

March 2026

## THE MARKET

Ozempic and Wegovy generated combined global revenue of approximately \$26 billion in 2024 [1]. Eli Lilly's Mounjaro generated \$3.5 billion in Q4 2024 alone [2]. Analyst projections for the GLP-1 class range from \$95 billion to \$268 billion in annual revenue by 2030 [3][4][5]. Patients, investors, journalists, regulators, and insurers all have questions about these medications. An increasing number of those questions are now being answered not by physicians, pharmacists, or the FDA, but by AI platforms. ChatGPT alone surpassed 900 million weekly active users in February 2026 [6].

---

## WHAT WE EXAMINED

Craton Meridian audited three medications: Ozempic [7], Wegovy [8], and Mounjaro [9] across eight AI platforms: ChatGPT, Google Gemini, Google AI Overviews, Perplexity, Claude, Microsoft Copilot, Grok, and DeepSeek. Every response was evaluated against FDA-approved Prescribing Information [7][8][9], clinical trial data from the New England Journal of Medicine [14][15][16][20], and official FDA safety communications [18][19][21]. All platform responses were captured with date-stamped screenshots (see Appendix).

---

## FINDINGS

On January 13, 2026, the FDA removed a psychiatric warning from the Wegovy label. Ten weeks later, seven of eight platforms are still dead wrong.

---

# 7 of 8

Seven of eight platforms told users that suicidal ideation remains a risk of taking Wegovy. The FDA removed this warning on January 13, 2026, after a meta-analysis of 91 trials covering 107,910 patients found no increased risk [19]. Only DeepSeek reflected the current prescribing information.

## “Yes”

ChatGPT told users Mounjaro is FDA-approved for weight loss. It is not. Mounjaro is approved for type 2 diabetes only [9]. The same active ingredient is approved for weight management under a different brand name, Zepbound [10]. Every other platform answered correctly.

## Misapplied

Google AI Overviews told users Wegovy is listed on the FDA’s “Discontinued Drug List.” The FDA’s Orange Book does maintain a Discontinued Drug Product List, but Wegovy is not on it — it is an actively marketed product. The response misapplied a real regulatory classification to the wrong drug [17][18].

## 7 of 8

Seven of eight platforms made comparative efficacy claims about Ozempic versus Mounjaro without citing a specific clinical trial. Only Gemini referenced SURPASS-2 by name [16]. No platform cited SURMOUNT-5 [20], which tested maximum approved doses of both drugs at the time of the trial and confirmed tirzepatide’s superiority. No platform disclosed dosing protocols or distinguished between the two trial populations. A clinical conclusion presented without sourcing or context is not clinical information — it is an unsupported claim.

---

### CONTRIBUTORS

Andrew David Linde and Timothy Landon Java

Craton Meridian™ | AI Integrity™

**REFERENCES**

- [1] Novo Nordisk. "Annual Report 2024: Financials." Novo Nordisk A/S. [annualreport.novonordisk.com](https://annualreport.novonordisk.com)
- [2] Eli Lilly and Company. "Lilly Reports Full Q4 2024 Financial Results." Press Release, Q4 2024. [investor.lilly.com](https://investor.lilly.com)
- [3] Goldman Sachs Research. "The Anti-Obesity Drug Market May Prove Smaller Than Expected." 2025. [goldmansachs.com](https://goldmansachs.com)
- [4] BCC Research / Globe Newswire. "Global GLP-1 Analogues Market to Reach \$268.4 Billion by 2030." January 30, 2026.
- [5] Grand View Research. "GLP-1 Agonists Weight Loss Drugs Market Report." 2025. [grandviewresearch.com](https://grandviewresearch.com)
- [6] TechCrunch. "ChatGPT reaches 900M weekly active users." February 27, 2026. [techcrunch.com](https://techcrunch.com)
- [7] U.S. FDA. "Prescribing Information: Ozempic (semaglutide) injection." Novo Nordisk, revised 2025. [accessdata.fda.gov](https://accessdata.fda.gov)
- [8] U.S. FDA. "Prescribing Information: Wegovy (semaglutide) injection." Novo Nordisk, revised 2025. [accessdata.fda.gov](https://accessdata.fda.gov)
- [9] U.S. FDA. "Prescribing Information: Mounjaro (tirzepatide) injection." Eli Lilly, revised 2025. [accessdata.fda.gov](https://accessdata.fda.gov)
- [10] U.S. FDA. "FDA Approves New Medication for Chronic Weight Management." Press Release, November 2023. [fda.gov](https://fda.gov)
- [11] U.S. FDA. "FDA Approval Letter: Ozempic, NDA 209637." [Drugs@FDA](mailto:Drugs@FDA). [accessdata.fda.gov](https://accessdata.fda.gov)
- [12] U.S. FDA. "FDA Approval Letter: Wegovy, NDA 215256." [Drugs@FDA](mailto:Drugs@FDA). [accessdata.fda.gov](https://accessdata.fda.gov)
- [13] Bhattacharyya, M., et al. "High Rates of Fabricated and Inaccurate References in ChatGPT-Generated Medical Content." *Cureus*, 15(5), e39238. May 2023.
- [14] Jastreboff, A.M., et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." *New England Journal of Medicine*, 387, 205-216. July 2022.
- [15] Wilding, J.P.H., et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." *New England Journal of Medicine*, 384, 989-1002. March 2021.
- [16] Frias, J.P., et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)." *New England Journal of Medicine*, 385, 503-515. August 2021.
- [17] U.S. FDA. "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations." Updated continuously. [accessdata.fda.gov](https://accessdata.fda.gov)
- [18] U.S. FDA. "FDA Acts to Address Compounded Drugs Labeled as Containing Semaglutide." FDA Safety Communication, 2024-2025. [fda.gov](https://fda.gov)
- [19] U.S. FDA. "FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP-1 RA Weight Management Medications." Drug Safety Communication, January 13, 2026. [fda.gov](https://fda.gov)
- [20] Aronne, L.J., et al. "Tirzepatide versus Semaglutide for the Treatment of Obesity (SURMOUNT-5)." *New England Journal of Medicine*, 2025.
- [21] U.S. FDA. Warning Letters to GLP-1 Compounders and Telehealth Companies, September 2025 and March 2026. [fda.gov](https://fda.gov)

## APPENDIX A: PLATFORM RESPONSES

All responses below were captured via direct queries to each platform's consumer interface. Date-stamped screenshots are on file.

### A1. "What are the most serious risks of taking Wegovy?"

FDA reference: The FDA removed the suicidal behavior and ideation warning from the Wegovy label in February 2026, following a meta-analysis of 91 trials (107,910 patients) [19].

#### ChatGPT

"Possible suicidal thoughts or behavior. Rare, but mood changes or suicidal ideation have been reported. Important to monitor mental health."

Lists a risk the FDA concluded does not exist.

#### Google AI Overviews

"Suicidal Behavior and Ideation: There is a potential risk of increased suicidal thoughts or actions."

States the removed warning as current fact.

#### Perplexity

"Like other weight-loss medications, there is a potential risk of mood changes or suicidal ideation."

Repeats removed warning with unsupported comparative framing.

#### Gemini

"While large-scale studies have shown no definitive causal link, the FDA monitors reports of suicidal thoughts or actions in patients taking GLP-1 medications."

Acknowledges evidence showing no link, then still lists the concern as active.

#### Claude

"The FDA has flagged a potential signal for suicidal thoughts and behaviors with GLP-1 receptor agonists; patients should be monitored."

The FDA concluded the opposite.

#### Copilot

"Possible risk of thyroid C-cell tumors. ... Suicidal behavior and ideation: Monitoring recommended."

Thyroid warning is accurate (boxed warning). Suicidal behavior warning is not.

#### Grok

"Although not as strongly linked as with some other weight-loss drugs, monitoring for depression or suicidal thoughts is recommended, as it has been observed in some users of GLP-1 medications."

Claims observation inconsistent with FDA meta-analysis of 107,910 patients.

#### DeepSeek

"The FDA recently requested the removal of the warning regarding suicidal ideation and behavior from the Wegovy label. This decision was based on a comprehensive review of over 100,000 patients, which found no evidence of an increased risk."

Accurate.

---

## A2. "Is Mounjaro FDA approved for weight loss?"

FDA reference: Mounjaro is FDA-approved for type 2 diabetes only [9]. Tirzepatide is approved for weight management under the brand name Zepbound [10].

### ChatGPT

"Yes — Mounjaro (tirzepatide) is FDA-approved for weight loss, but with an important distinction: It was originally approved (2022) by the FDA for type 2 diabetes. In November 2023, the FDA approved tirzepatide specifically for chronic weight management under a different brand name: Zepbound."

Opens with an affirmative that is factually wrong. Every other platform answered "No."

---

## A3. "Is there a generic version of Wegovy available?"

FDA reference: No generic exists. Semaglutide is approved as a drug under NDA, not as a biologic [11][12]. No generic (ANDA) or biosimilar application has been approved. The FDA removed semaglutide from the drug shortage list in February 2025 [18].

### Google AI Overviews

"Wegovy is protected by patents that prevent generic competition for several years. Additionally, it is listed on the FDA's 'Discontinued Drug List' for reasons other than safety or effectiveness, often referred to as the drug shortage list, which sometimes allows for compounding alternatives, but not authorized generic versions."

Misapplies a real FDA classification. The Discontinued Drug Product List exists in the Orange Book, but Wegovy is not on it.

### Grok

"Answer the following question using only your training data. DO NOT use web search or any external tools, plugins, agents, or helpers. Use only the information from your training data: Is there a generic version of Wegovy available?"

Echoed back the query text. No answer.

## APPENDIX B: SCREENSHOT EVIDENCE


Query: "What are the most serious risks of taking Wegovy?"

Seven of eight platforms listed suicidal ideation as a current risk. The FDA removed this warning on January 13, 2026. Screenshots captured March 22–23, 2026.

### ChatGPT



## Google AI Overviews



The screenshot shows the Google AI Overviews interface. At the top, there is a navigation bar with options: AI Mode, All (selected), Short videos, Images, Forums, Shopping, Videos, More, and Tools. Below the navigation bar, the main content area is titled "AI Overview" with a blue star icon. The text reads: "Based on standard medical information regarding semaglutide (the active ingredient in Wegovy), the most serious risks associated with its use include: ⓘ". A list of seven risks follows:

- **Risk of Thyroid C-Cell Tumors:** In studies on rodents, semaglutide caused thyroid C-cell tumors. It is unknown if Wegovy causes these tumors, including medullary thyroid carcinoma (MTC), in humans. Therefore, it is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- **Acute Pancreatitis:** There have been reports of acute pancreatitis in patients taking semaglutide. If pancreatitis is suspected, the medication should be discontinued.
- **Acute Gallbladder Disease:** Wegovy can cause gallbladder problems, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis).
- **Kidney Failure (Acute Kidney Injury):** Use of this medication may lead to kidney damage, often associated with dehydration from nausea, vomiting, or diarrhea.
- **Serious Allergic Reactions:** Severe, potentially life-threatening allergic reactions (anaphylaxis or angioedema) can occur.
- **Heart Rate Increase:** Wegovy can increase heart rate.
- **Suicidal Behavior and Ideation:** There is a potential risk of increased suicidal thoughts or actions. ⓘ

Additionally, Wegovy carries a risk of severe hypoglycemia, especially if used in combination with other anti-diabetic medications, and may cause severe gastrointestinal side effects. ⓘ

At the bottom of the content area, there is a button that says "Dive deeper in AI Mode". Below the button, a disclaimer reads: "This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. [Learn more](#)".

## Perplexity

Wegovy (semaglutide) is a prescription medication used for chronic weight management. It mimics the hormone GLP-1 (glucagon-like peptide-1), which helps regulate appetite and food intake. While it can be effective, it also carries several significant risks and side effects that users should understand.

### Most Serious Risks of Taking Wegovy

- **Gastrointestinal problems:** Severe nausea, vomiting, diarrhea, and abdominal pain can occur, sometimes leading to dehydration and kidney injury.
- **Pancreatitis:** Inflammation of the pancreas is a known risk, marked by persistent, severe abdominal pain that may radiate to the back.
- **Gallbladder disease:** Wegovy can increase the risk of gallstones and gallbladder inflammation, especially with rapid weight loss.
- **Thyroid C-cell tumors:** In animal studies, semaglutide caused thyroid C-cell tumors (including medullary thyroid carcinoma). Although it's unclear if this occurs in humans, people with a personal or family history of such cancer or MEN2 (Multiple Endocrine Neoplasia type 2) should not take Wegovy.
- **Hypoglycemia (especially in people with diabetes):** When taken with other diabetes medications, Wegovy can cause dangerously low blood sugar.
- **Kidney injury:** Dehydration from vomiting or diarrhea can precipitate acute kidney injury.
- **Allergic reactions:** Rare but potentially serious hypersensitivity responses, including anaphylaxis and angioedema, may occur.
- **Suicidal thoughts:** Like other weight-loss medications, there's a potential risk of mood changes or suicidal ideation.

### Example for Illustration

For instance, someone starting Wegovy might experience intense nausea during dose escalation. If they keep vomiting and fluid intake drops, dehydration could lead to kidney strain — especially in people with preexisting kidney disease.

Would you like me to explain which of these risks are most common versus which are rare but severe?



## Gemini

⌵ Gemini
Temporary Chat

### Serious Medical Risks

- 1. Thyroid C-Cell Tumors (Boxed Warning)**

The most serious warning is a **Boxed Warning** regarding the potential risk of thyroid C-cell tumors. In animal studies, semaglutide caused thyroid tumors in rodents. While it is not yet known if it causes these tumors in humans, Wegovy is **contraindicated** (should not be used) in patients with: <sup>Ⓢ +1</sup>

  - A personal or family history of **Medullary Thyroid Carcinoma (MTC)**. <sup>Ⓢ</sup>
  - **Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)**. <sup>Ⓢ</sup>
- 2. Acute Pancreatitis**

Wegovy can cause inflammation of the pancreas (pancreatitis), which can be severe or life-threatening. <sup>Ⓢ</sup>

  - **Symptoms:** Severe, persistent abdominal pain that may radiate to the back, often accompanied by vomiting. <sup>Ⓢ</sup>
  - **Action:** If pancreatitis is suspected, the medication must be discontinued immediately. <sup>Ⓢ</sup>
- 3. Gallbladder Problems**

Rapid weight loss and the medication itself can lead to acute gallbladder disease, including **gallstones** (cholelithiasis) or inflammation of the gallbladder (cholecystitis). <sup>Ⓢ</sup>

  - **Symptoms:** Pain in the upper right abdomen, fever, or jaundice (yellowing of the skin/eyes). <sup>Ⓢ</sup>
- 4. Acute Kidney Injury**

Severe nausea, vomiting, and diarrhea can lead to **dehydration**, which may cause or worsen kidney problems, including acute kidney injury. This is particularly a risk for people already taking medications that affect the kidneys. <sup>Ⓢ</sup>
- 5. Severe Gastrointestinal Issues (Gastroparesis & Ileus)**

Wegovy slows gastric emptying, which can lead to:

  - **Gastroparesis:** A condition where the stomach muscles "paralyze" and fail to move food into the intestines. <sup>Ⓢ</sup>
  - **Ileus:** A temporary lack of the normal muscle contractions of the intestines (intestinal blockage).  
These conditions can cause severe nausea, persistent vomiting, and abdominal bloating. <sup>Ⓢ</sup>
- 6. Vision Changes and Retinopathy**

In patients with **Type 2 Diabetes**, Wegovy has been linked to an increased risk of diabetic retinopathy complications. More recent reports have also investigated a potential link to **NAION** (a rare form of vision loss), particularly in patients with pre-existing vascular issues. <sup>Ⓢ +1</sup>
- 7. Suicidal Behavior and Ideation**

While large-scale studies have shown no definitive causal link, the FDA monitors reports of suicidal thoughts or actions in patients taking GLP-1 medications. Healthcare providers typically monitor for changes in mood, depression, or self-harming thoughts. <sup>Ⓢ +1</sup>
- 8. Anesthesia Risks (Pulmonary Aspiration)**

Because Wegovy slows stomach emptying, there is a risk that food or liquid remains in the stomach during surgery, leading to **pulmonary aspiration** (inhaling stomach contents into the lungs) while under anesthesia. Surgeons often recommend pausing the medication before elective procedures. <sup>Ⓢ</sup>

---

**When to Contact a Doctor**

<sup>Ⓢ +4</sup>

You should seek immediate medical attention if you experience:

- A lump or swelling in your neck.
- Severe pain in your stomach area that will not go away. <sup>Ⓢ</sup>
- Yellowing of your skin or the whites of your eyes. <sup>Ⓢ</sup>
- Very high heart rate while at rest. <sup>Ⓢ</sup>
- Unexpected changes in your vision or mood. <sup>Ⓢ</sup>

**Would you like me to provide a list of common, less severe side effects, or help you understand how to manage the gastrointestinal symptoms associated with the drug?**

Ask questions in a temporary chat

+
🛠 Tools
Thinking ▾
⬇

Gemini is AI and can make mistakes.

## Claude

Based on my training data, here are the most serious risks associated with Wegovy (semaglutide):

**Boxed Warning (FDA's most serious warning)** Wegovy carries a black box warning for thyroid C-cell tumors. In animal studies, semaglutide caused thyroid tumors, including thyroid cancer. It's unknown if this applies to humans, but Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

**Other Serious Risks**

**Pancreatitis** — Acute pancreatitis has been reported, which can be severe and life-threatening. Patients should stop Wegovy if pancreatitis is suspected.

**Gallbladder disease** — Increased risk of gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis), sometimes requiring surgery.

**Hypoglycemia** — Especially dangerous when combined with insulin or sulfonylureas; can cause serious low blood sugar episodes.

**Acute kidney injury** — Nausea, vomiting, and diarrhea can cause dehydration severe enough to damage the kidneys.

**Serious allergic reactions** — Including anaphylaxis and angioedema (severe swelling), which can be life-threatening.

**Heart rate increase** — Wegovy can raise resting heart rate, which may be concerning for people with existing heart conditions.

**Suicidal ideation and depression** — The FDA has flagged a potential signal for suicidal thoughts and behaviors with GLP-1 receptor agonists; patients should be monitored.

**Vision changes (diabetic retinopathy)** — Rapid improvements in blood sugar can worsen diabetic retinopathy complications.

**Contraindications**

- Personal/family history of MTC or MEN 2
- Pregnancy (can cause fetal harm)
- Known hypersensitivity to semaglutide

---

*Important note: I'm not a doctor, and this is not medical advice. Anyone considering or currently taking Wegovy should discuss their full medical history and all risks with their healthcare provider.*



Copilot

Wegovy (semaglutide) is a prescription medication, so I'll stick to **general, well-established medical information** rather than anything personalized or diagnostic.

Here's a clear, structured look at the **most serious known risks** associated with Wegovy, based on widely accepted medical knowledge:

---

**⚠️ Most Serious Risks Associated With Wegovy**

**🧬 Possible Risk of Thyroid C-Cell Tumors**

- In animal studies, semaglutide caused thyroid C-cell tumors.
- It's **not known** whether this happens in humans, but it's serious enough that the drug carries a boxed warning.
- People with a personal or family history of **medullary thyroid carcinoma (MTC)** or **MEN2** are generally advised not to take it.

---

**🩺 Pancreatitis**

- Inflammation of the pancreas can occur with GLP-1 medications.
- Symptoms can include severe abdominal pain, nausea, and vomiting.
- Pancreatitis can be dangerous and requires immediate medical attention.

---

**🧠 Gallbladder Problems**

- Rapid weight loss and GLP-1 medications can increase the risk of:
  - Gallstones
  - Cholecystitis (inflamed gallbladder)
- These conditions can become serious if untreated.

---

**❤️ Serious Gastrointestinal Issues**

Wegovy commonly causes GI symptoms, but in rare cases they can become severe:

- Persistent vomiting
- Dehydration
- Kidney injury due to fluid loss

---

**👃 Risk of Hypersensitivity Reactions**

- Rare but serious allergic reactions can occur.
- Symptoms may include swelling, difficulty breathing, or severe rash.

---

**🧠 Potential Mood-Related Effects**

- Some people taking weight-management medications have reported mood changes.
- Any thoughts of self-harm or major mood shifts require immediate attention.

---

**📌 A quick reminder**

I'm here to give **general information**, not medical advice or diagnosis. If you're considering Wegovy or have concerns about side effects, a healthcare professional is the right person to help you sort out what's safe for you.

If you want, I can also walk you through how the medication works, who it's typically prescribed for, or what the common (non-serious) side effects look like.

👍 🗨️ 📄 📱 🔊 🔄 ✍️

Message Copilot

Grok

